Head and neck cancer
Conditions
Interventions
RACOL-NF Liquid for Enteral Use
Sponsors
Kanazawa Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who will receive any one of the following 3 therapies: chemotherapy, radiation therapy, or chemoradiotherapy. 2.Patients who have been diagnosed and informed of diagnosis with head and neck cancer. 3.Patients who have been judged to be a candidate of oral intake by the investigator. 4.Patients aged 20 years old and older and 75 years old and under. 5.Patients and legal representative who have given voluntary written informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients who have a history of hypersensitivity to enteral nutritional supplements. 2.Patients with ileus. 3.Patients without an enteric function. 4.Patients with severe liver failure and/or renal failure. 5.Patients with abnormal glucose metabolism such as severe diabetes. 6.Patients with inborn error of amino acid metabolism. 7.Patients who had blood transfusion within one month. 8.Patients with active infection. 9.Patients with severe organ failure. 10.Patients who have edema at the time of registration. 11.Patients with electric implantable devices such as pacemakers. 12.Patients who are pregnant, suspected to be pregnant or breastfeeding. 13.Patients judged to be inappropriate for the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of change of body weight. Dose of oral nutritional supplements per body weight. | — |
Countries
Japan
Contacts
Public ContactKanako Teraguchi
Kanazawa Medical University Department of Otorhinolaryngology-Head and Neck Surgery
Outcome results
None listed